Antimicrobial resistance: animal use of antibiotics

Author(s):  
Lord Soulsby

The evolution of resistance to microbes is one of the most significant problems in modern medicine, posing serious threats to human and animal health. The early work on the use of antibiotics to bacterial infections gave much hope that infectious diseases were no longer a problem, especially in the human field. However, as their use, indeed over use, progressed, resistance (both mono-resistance and multi-resistance), which was often transferable between different strains and species of bacteria, emerged. In addition, the situation is increasingly complex, as various mechanisms of resistance, including a wide range of β -lactamases, are now complicating the issue. The use of antibiotics in animals, especially those used for growth promotion, has come in for serious criticism, especially those where their use should be reserved for difficult human infections. To lend control, certain antibiotic growth promoters have been banned from use in the EU and the UK.It is now a decade since the UK House of Lords Science and Technology Committee (1998) highlighted concerns about antimicrobial resistance and the dangers to human health of resistant organisms derived from animals fed antibiotics for growth promotion or the treatment of infectious diseases. The concern expressed in the House of Lords report was similar to that in other major reports on the subject, for example from the World Health Organization, the Wellcome Foundation, the Advisory Committee on the Microbiological Safety of Food and the Swann Report (1969) in which it was recommended that antibiotics used in human medicine should not be used as growth promoters in animals. At the press conference to launch the Lord’s Report it was emphasized that unless serious attention was given to dealing with resistance ‘we may find ourselves returning to a pre-antibiotic era’. The evolution of resistance is one of the significant problems in modern medicine, a much changed situation when the early work on antibiotics gave hope that infectious diseases were no longer a problem, especially in the human field. Optimism was so strong that the Surgeon General of the USA, William H Stewart, in 1969 advised the US Congress that ‘it is time to close the book on infectious diseases and to declare that work against the pestilence is over’. This comment was not only mistaken but it was also damaging to human health undertakings and also reduced funding for research on infectious diseases.Despite the widespread support for and dependence on antibiotics, resistance was increasingly reported worldwide and to recognize the global problem a group of medical workers established in 1981, at Tufts University, the Alliance for the Prudent use of Antibiotics (APUA). This now has affiliated chapters on over 60 countries, many in the developing world. APUA claims to be the ‘world’s leading organization conducting antimicrobial resistance research, education, capacity building and advocacy at the global and grass roots levels’.

2019 ◽  
Vol 9 (12) ◽  
pp. 2486 ◽  
Author(s):  
Mónica Cartelle Gestal ◽  
Margaret R. Dedloff ◽  
Eva Torres-Sangiao

Infectious diseases are the primary cause of mortality worldwide. The dangers of infectious disease are compounded with antimicrobial resistance, which remains the greatest concern for human health. Although novel approaches are under investigation, the World Health Organization predicts that by 2050, septicaemia caused by antimicrobial resistant bacteria could result in 10 million deaths per year. One of the main challenges in medical microbiology is to develop novel experimental approaches, which enable a better understanding of bacterial infections and antimicrobial resistance. After the introduction of whole genome sequencing, there was a great improvement in bacterial detection and identification, which also enabled the characterization of virulence factors and antimicrobial resistance genes. Today, the use of in silico experiments jointly with computational and machine learning offer an in depth understanding of systems biology, allowing us to use this knowledge for the prevention, prediction, and control of infectious disease. Herein, the aim of this review is to discuss the latest advances in human health engineering and their applicability in the control of infectious diseases. An in-depth knowledge of host–pathogen–protein interactions, combined with a better understanding of a host’s immune response and bacterial fitness, are key determinants for halting infectious diseases and antimicrobial resistance dissemination.


2019 ◽  
Vol 40 (2) ◽  
pp. 73
Author(s):  
Steven P Djordjevic ◽  
Branwen S Morgan

Antimicrobial resistance (AMR) threatens modern medicine as we know it. AMR infections may ultimately be untreatable and routine surgeries will become inherently risky1. By 2050 more people may die of drug-resistant infections (DRIs) every year than of cancer, which equates to more than 10 million annual deaths globally2 and the World Bank has estimated that AMR could cost the global economy $1 trillion every year after 2030. DRIs also lead to an increase in the length of hospital stays, the use of more toxic or costly antibiotics and an increased likelihood of death3. BRIC nations (Brazil, Russia, India, China) and socio-economically challenged countries and people who already have higher rates of infectious diseases will feel the greatest impact2. Indeed, AMR has been likened to the 2008 global financial crisis on an annual repeat cycle. That is because the effects of AMR are not just confined to the human medical sector. The veterinary sector is also reliant on the availability of antimicrobials to treat infectious diseases in companion and food-producing animals.


2021 ◽  
Author(s):  
Chaonan Li ◽  
Yite Li ◽  
Qihang Wu ◽  
Tingting Sun ◽  
Zhigang Xie

Bacterial infectious diseases and antimicrobial resistance seriously endanger human health, so alternative therapies for bacterial infections are urgently needed. Recently, photodynamic therapy against bacteria has shown great potential because of...


2021 ◽  
Vol 75 (1) ◽  
Author(s):  
Eric P. Skaar

Infectious diseases are a leading cause of global morbidity and mortality, and the threat of infectious diseases to human health is steadily increasing as new diseases emerge, existing diseases reemerge, and antimicrobial resistance expands. The application of imaging technology to the study of infection biology has the potential to uncover new factors that are critical to the outcome of host-pathogen interactions and to lead to innovations in diagnosis and treatment of infectious diseases. This article reviews current and future opportunities for the application of imaging to the study of infectious diseases, with a particular focus on the power of imaging objects across a broad range of sizes to expand the utility of these approaches. Expected final online publication date for the Annual Review of Microbiology, Volume 75 is October 2021. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.


Author(s):  
Dilys Morgan ◽  
Ruth Lysons ◽  
Hilary Kirkbride

Surveillance (derived from the French word surveiller, meaning to watch over) is the ‘ongoing scrutiny, generally using methods distinguished by their practicability, uniformity, and frequently their rapidity, rather than for complete accuracy. Its main purpose is to detect changes in trend or distribution in order to initiate investigative, (preventive) or control or measures’ (Last 1988).Understanding the burden and detecting changes in the incidence of human and animal infections utilises a number of surveillance mechanisms, which rely on voluntary and/or statutory reporting systems. These include international as well as national surveillance schemes for outbreaks of infectious disease and laboratory-confirmed infections, enhanced surveillance schemes for specificzoonoses and notification of specified infectious diseases.


2015 ◽  
Vol 370 (1670) ◽  
pp. 20140082 ◽  
Author(s):  
Laura J. Shallcross ◽  
Simon J. Howard ◽  
Tom Fowler ◽  
Sally C. Davies

Antibiotics underpin all of modern medicine, from routine major surgery through to caesarean sections and modern cancer therapies. These drugs have revolutionized how we practice medicine, but we are in a constant evolutionary battle to evade microbial resistance and this has become a major global public health problem. We have overused and misused these essential medicines both in the human and animal health sectors and this threatens the effectiveness of antimicrobials for future generations. We can only address the threat of antimicrobial resistance (AMR) through international collaboration across human and animal health sectors integrating social, economic and behavioural factors. Our global organizations are rising to the challenge with the recent World Health Assembly resolution on AMR and development of the Global Action plan but we must act now to avoid a return to a pre-antibiotic era.


2021 ◽  
pp. 269-280
Author(s):  
Lea Knez ◽  
◽  
Jelka Reberšek Gorišek ◽  
Nina Gorišek Miksić ◽  
◽  
...  

Antimicrobial resistance is one of the significant threats to human health. To maintain the benefits of modern medicine, which hardly relies on antimicrobial treatments, all the stakeholders have to work together towards containing antimicrobial resistance. There are three fundamental strategies to tackle antimicrobial resistance: prudent and supervised antimicrobial use, improved hand hygiene, and improved cleaning of the patient environment.


Sensors ◽  
2021 ◽  
Vol 21 (19) ◽  
pp. 6625
Author(s):  
Karine Caron ◽  
Pascal Craw ◽  
Mark B. Richardson ◽  
Levente Bodrossy ◽  
Nicolas H. Voelcker ◽  
...  

Antimicrobial resistance (AMR) is threatening modern medicine. While the primary cost of AMR is paid in the healthcare domain, the agricultural and environmental domains are also reservoirs of resistant microorganisms and hence perpetual sources of AMR infections in humans. Consequently, the World Health Organisation and other international agencies are calling for surveillance of AMR in all three domains to guide intervention and risk reduction strategies. Technologies for detecting AMR that have been developed for healthcare settings are not immediately transferable to environmental and agricultural settings, and limited dialogue between the domains has hampered opportunities for cross-fertilisation to develop modified or new technologies. In this feature, we discuss the limitations of currently available AMR sensing technologies used in the clinic for sensing in other environments, and what is required to overcome these limitations.


Author(s):  
Mahnoor Patel

Vaccination is one of the major success stories of modern medicine. It has the ability for reducing the incidence of infectious diseases such as measles, and helps in eradicating others like smallpox. Conventional vaccine approaches have not been as effective against rapidly evolving pathogens like influenza or emerging disease threats such as the Ebola, Zika Viruses or Novel Coronavirus. RNA based vaccines could have an impact in these areas due to their shorter manufacturing times and greater effectiveness. Beyond infectious diseases RNA vaccines have potential as Novel therapeutic options for major disease such as cancer for development of personalized medicine. At the time of epidemic like Ebola or pandemic like 2019-Novel Coronavirus (2019-nCoV) mRNA vaccine technology is the most effective way to develop a vaccine at the possible earliest time. As compared to the traditional way of vaccine development, next generation technology for developing vaccine is more essential. A novel pandemic cause by virus has been reported in Wuhan, China; in late December 2019. Within time duration of few weeks, the newly identified virus designated as 2019-Novel Coronavirus (2019-nCoV) and it was declared as pandemic by World Health Organization (WHO). At the time of late January 2020, WHO announced it as the international emergency outbreak because of the rapid spread and increases at the global level. There is no any preventive vaccine is present or any approved therapy/treatment for this viral emergency which is very infectious globally. The principle behind RNA vaccine is to use natural mRNA as a data carrier which can give instructions to the human body for the production of its proteins to fight against various diseases. RNA based vaccines provide good safety when it comes to their delivery in the cytoplasm. RNA vaccines comprise as mRNA vaccine which can offer robust safety profile with minimal genetic construction to express the desired antigen. There are few mRNA vaccines which were developed by few Biotechnology companies, showing positive results against COVID-19 and it is there in 4th phase clinical trial which possibly be the first vaccine available in the market in between mid-2021.


Sign in / Sign up

Export Citation Format

Share Document